New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarin Journal Articles

abstract

• The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing.British Journal of Pharmacology (2005) 144, 1017–1028. doi:10.1038/sj.bjp.0706153

authors

• Bates, Shannon M
• Weitz, Jeffrey

status

• published 

publication date

• April 2005

has subject area

• 1115 Pharmacology and Pharmaceutical Sciences (FoR)
• Animals (MeSH)
• Anticoagulants (MeSH)
• Drugs, Investigational (MeSH)
• Heparin, Low-Molecular-Weight (MeSH)
• Humans (MeSH)
• Pharmacology & Pharmacy (Science Metrix)
• Venous Thrombosis (MeSH)
• Warfarin (MeSH)

published in

• British Journal of Pharmacology  Journal

keywords

• Animals
• Anticoagulants
• Drugs, Investigational
• Heparin, Low-Molecular-Weight
• Humans
• Venous Thrombosis
• Warfarin

Digital Object Identifier (DOI)

• 10.1038/sj.bjp.0706153

start page

• 1017

end page

• 1028

volume

• 144

issue

• 8